• allergen;
  • allergy;
  • antihistamine;
  • anti-leukotriene;
  • aspirin;
  • asthma;
  • BSACI;
  • cat allergen;
  • child;
  • corticosteroid;
  • cromoglicate;
  • decongestant;
  • guideline;
  • house dust mite;
  • IgE;
  • immunotherapy;
  • ipratropium bromide;
  • lactation;
  • nitric oxide;
  • occupational;
  • pregnancy;
  • rhinitis;
  • rhinosinusitis;
  • sinusitis;
  • skin prick test;
  • sublingual immunotherapy;
  • surgery


  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

This guidance for the management of patients with allergic and non-allergic rhinitis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and paediatricians practicing in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are clinical classification of rhinitis, aetiology, diagnosis, investigations and management including subcutaneous and sublingual immunotherapy. There are also special sections for children, co-morbid associations and pregnancy. Finally, we have made recommendations for potential areas of future research.


  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Rhinitis significantly reduces quality of life (QOL) [1], interferes with both attendance and performance at school and work [2, 3] and results in substantial NHS costs [4]. The nose is the gateway to the respiratory tract and rhinitis is associated with symptoms arising from the sinuses [5], middle ear [6], the nasopharynx and lower airways [7]. Occupational rhinitis often precedes the development of occupational asthma. Both allergic rhinitis (AR) and non-AR are risk factors for the development of asthma [7]. Rhinosinusitis can also be the presenting complaint of potentially severe systemic disorders such as Wegener's granulomatosis, sarcoidosis and Churg–Strauss syndrome [8]. Therefore, all patients presenting with nasal symptoms require appropriate treatment based on an accurate diagnosis. Separate British Society for Allergy and Clinical Immunology (BSACI) guidelines on rhinosinusitis and nasal polyposis will also be published.

These guidelines for the management of patients with rhinitis are intended for use by physicians treating allergic conditions. Evidence for the recommendations was obtained by using electronic literature searches using the primary key words – rhinitis and non-AR. Further searches were carried out by combining these search terms with allergy, asthma, immunotherapy, sublingual immunotherapy (SLIT), corticosteroid, antihistamine, anti-leukotriene, ipratropium bromide, decongestant, cromoglicate, cat, house dust mite (HDM), anti-IgE, child, pregnancy, lactation, surgery and aspirin. Each article was reviewed for suitability for inclusion in the guideline. The recommendations were evidence graded at the time of preparation of these guidelines. The grades of recommendation and the levels of evidence are defined as in our previous guideline on urticaria [9]. During the development of these guidelines, a web-based system was used to allow consultation with all BSACI members. The draft guidelines were amended by the Standards of Care Committee (SOCC) after careful consideration of all comments and suggestions. Where evidence was lacking, a consensus was reached among the experts on the committee. Conflicts of interests were recorded by the SOCC; none jeopardized unbiased guideline development.

Executive summary and recommendations

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Allergic rhinitis

  • Is common and affects over 20% of the UK population.
  • Affects QOL, school and work attendance and performance.
  • Is diagnosed by history and examination backed up by specific allergy tests.
  • Is a risk factor for the development of asthma.
  • Topical nasal corticosteroids are the treatment of choice for moderate to severe disease. (Grade of recommendation=A)
  • Standardized allergy education improves disease-specific QOL. (Grade of recommendation=C)
  • Treatment failure may be related to poor technique in the use of nasal sprays and drops and therefore appropriate training is imperative. (Grade of recommendation=C)
  • Treatment of rhinitis is associated with benefits for asthma. (Grade of recommendation=A)
  • Immunotherapy is highly effective in selected cases. (Grade of recommendation=A)
  • Occupational rhinitis often precedes the development of occupational asthma.

Non-allergic rhinitis

  • Has a multifactorial aetiology.
  • Is a risk factor for the development of asthma.
  • If eosinophilic, usually responds to treatment with corticosteroids.
  • May be a presenting complaint for systemic disorders such as Wegener's granulomatosis, Churg–Strauss and sarcoidoisis.

Infective rhinitis

  • Can be caused by viruses, and less commonly by bacteria, fungi and protozoa.
  • Is often more severe in allergic patients especially if infection occurs at the time of allergen exposure.


  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Rhinitis describes inflammation of the nasal mucosa but is clinically defined by symptoms of nasal discharge, itching, sneezing and nasal blockage or congestion. As the sinus linings are also usually involved, the term rhinosinusitis is more accurate, but is conventionally reserved for more severe disease. Rhinitis can be classified into allergic, non-allergic and infective. However, acute viral upper respiratory infections are not considered in detail in this document.

Classification and aetiology of rhinitis

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Allergic rhinitis

The prevalence of AR has increased over the last three decades [10, 11]. At most risk are those with atopy, with a family history of rhinitis, first-born children and immigrants [12–14]. AR is the predominant form in children, but accounts for about a third of rhinitis cases in adults.

In AR, the immediate reaction resulting from IgE-mediated mast cell degranulation and mediator release is rapid and leads to sneezing, rhinorrhoea, itch and nasal blockage. The late-phase reaction involves inflammation, with an eosinophilic infiltrate [15–17]. Symptoms are chronic obstruction, hyposmia, post-nasal mucous discharge and nasal hyper-reactivity. Figure 1 illustrates the mechanisms leading to AR. Table 1 lists the common allergic triggers for rhinitis, and Table 2 specifies the common causes of occupational rhinitis.


Figure 1.  Mechanism of allergic rhinitis. Sensitized patients with allergic rhinitis have IgE antibodies for specific allergen(s) bound to receptors on the surface of mast cells. On re-exposure to the specific allergen(s), cross-linking of adjacent IgE molecules occurs, and mast cell degranulation (rupture) takes place, releasing a variety of chemical mediators that may be preformed (e.g. histamine) or newly synthesized (e.g. leukotrienes, prostaglandins). These chemicals give rise to the typical immediate symptoms experienced by the patient. In many patients, there is also a late-phase reaction in which T helper type 2 cytokines induce an eosinophilic inflammatory infiltrate, similar to that seen in asthma. This results in chronic, less obvious symptoms. GM, granulocyte macrophage; CSF, cerebrospinal fluid; PAF, platelet-activating factor.

Download figure to PowerPoint

Table 1.   Allergic triggers for rhinitis
Trigger typesOrigin/specific example of triggerType of rhinitis caused
MitesHouse dust mite, storage mites, allergen in mite fecal pelletsMajor causes of perennial rhinitis
PollensTrees, grasses, shrubs, weedsMain causes of seasonal rhinitis; cross-reactivity among pollens
AnimalsCats, dogs, horses Mice, ratsAllergen in sebaceous glands and saliva Allergen mainly in urine
Fungi (moulds)Alternaria, Cladosporium, AspergillusSeasonal and/or perennial symptoms
Occupational induced (see also Table 2)Flour, latex, laboratory animals, wood dust, enzymes, other airborne proteinsReversible with early diagnosis and avoidance but becomes chronic and irreversible if exposure is prolonged [206] May progress to asthma. Diagnosis based on symptom diary cards and provocation tests (Table 4)
Occupation aggravatedSmoke, cold air, formaldehyde, sulphur dioxide, ammonia, glues, solvents, etc. [204, 205]Pre-existing rhinitis can be aggravated by work-place irritants
Table 2.   Common causes of occupational rhinitis
AgentsHigh MWLow MWIndustry
Animal proteinsMouse, rat, guinea pig, crabs, etc. urinary and epithelial proteins Laboratory research, animal breeding [207–209], crab processing industry [210]
Vegetable proteinsWheat and other cereal flours and grains, latex [51] Baking [211], milling, food processing, hospital workers
EnzymesProtease, amylase, cellulase, lipase Food processing, detergent manufacture, pharmaceuticals
PharmaceuticalsAntibiotics, morphine, cimetidine Pharmaceutical manufacture and dispensing
Chemicals Diisocyanates, colophony fumes, (trimellitic) acid anhydrides (TMA) [212], cyanoacrylates, epoxy resins, alkyd/polyunsatu-rated polyester resins [213]Spray painting, electronic soldering, plastics and paint manufacture, vinyl flooring, resin production

The WHO ARIA workshop ‘Allergic Rhinitis and its impact on Asthma’ [18] suggested a new classification of AR based on frequency and severity of symptoms as these are the major factors involved in determining treatment; see Fig. 2. These recommendations have been validated subsequently [19]. A clinical classification of seasonal and perennial rhinitis is useful in UK practice, especially for diagnosis and immunotherapy, and can be used alongside the ARIA classification.


Figure 2.  Classification of allergic rhinitis. Each box may be further sub-classified into seasonal or perennial.

Download figure to PowerPoint

The ARIA recommendations emphasized the concept of treating ‘one airway, one disease’ with a similar unified therapeutic approach to the management of co-morbidities such as asthma, sinusitis, otitis media and conjunctivitis [20].

Infective rhinitis

Any cause of congestion of the nasal mucosa can lead to occlusion of the sinus ostia, predisposing to facial pain, sinusitis and/or eustachian tube dysfunction. The causes and disease patterns of infective rhinitis are summarized in Table 3.

Table 3.   Infective causes of rhinitis
Infective agent typeExamples of infective agentCaused disease pattern
  1. COPD, chronic obstructive pulmonary disease; CT, computed tomography; RSV, respiratory syncytial virus.

VirusesCommon cold viruses, e.g. rhinovirus, coronaviruses, RSV, etc.Sinus changes on CT scan remain for up to 6 weeks after the infection [214] 0.5–2% become superinfected by bacteria [215] ‘Colds’ may exacerbate asthma and COPD [216, 217] Children average 6–8 ‘colds’ per year [218]
BacteriaStreptococcus, Haemophilus, Moraxella, Staphylococcus, MycobacteriaAcute infection causes nasal obstruction, facial pain, crusting, purulent discharge Can progress to rhinosinusitis
Fungi and other opportunistic infectionsAspergillusRarely cause symptoms; mainly affect immuno-suppressed individuals [219]

Non-allergic rhinitis

The numerous diagnoses in this category need to be borne in mind for patients with negative skin prick tests (SPTs). Table 4 summarizes the causes and disease patterns of non-AR.

Table 4.   Types and possible triggers of non-allergic rhinitis
TypeSuggested triggers/causeSigns/symptoms
  1. ACE, angiotensin-converting enzyme; HRT, hormone replacement therapy; NSAID, non-steroidal anti-inflammatory drugs; SLE, systemic lupus erythematous.

Eosinophilic or non-allergic rhinitis with eosinophilia syndrome (NARES)50% develop aspirin sensitive disease with asthma and nasal polyposis later in life [220]Skin tests negative but nasal smears show eosinophilia Perennial symptoms with paroxysmal episodes. About 50% have bronchial hyper-reactivity [220]
Autonomic (vasomotor)Triggered by physical/chemical agentsMore common in middle age with clear rhinorrhoea especially in the morning. Less favourable course than allergic. Possibly caused by parasympathetic hyperactivity [221]
Drugsα-adrenergic blockers, ACE inhibitors, chlorpromazine Cocaine Nasal decongestants (with prolonged use) Aspirin/NSAIDsNasal blockage Rhinorrhoea, crusting, pain and nasal septum perforation reduced olfaction [222] Rhinitis medicamentosa with chronic nasal blockage [126] Acute rhinitis symptoms ± asthma
HormonalPregnancy [157], puberty, HRT, contraceptive pill [223, 224] Possibly hypothyroidism, acromegaly [225, 226]All can cause nasal blockage and/or rhinorrhoea
FoodAlcohol, spicy foods, pepper, sulphitesRhinorrhoea, facial flushing Gustatory rhinorrhoea
AtrophicKlebsiella Ozonae [227] or secondary to trauma, surgery, radiationFoul-smelling odour, crusting, hyposmia, nasal blockage [228]
Primary mucus defectCystic fibrosisChildren with polyps must be screened for cystic fibrosis [229]
Primary ciliary dyskinesiasKartagener and Young syndromesRhinosinusitis, bronchiectasis and reduced fertility
Systemic/inflammatorySjogren, SLE, rheumatoid arthritis, Churg–Strauss [230]Nasal blockage Polyps, sinusitis, asthma, eosinophilia
ImmunodeficiencyAntibody deficiencyChronic infective sinusitis
MalignancyLymphoma, melanoma, squamous cell carcinomaBloody, purulent discharge, pain and nasal blockage – symptoms may be unilateral
Granulomatous diseasesSarcoidosis Wegener's disease [231]External nasal swelling or collapse, sinusitis, swelling, crusting, bleeding, septal perforation
Structural abnormalitiesNasal septal deviationUnilateral nasal obstruction unlikely to present unless additional cause, e.g. rhinitis
IdiopathicUnknown cause – diagnosis of exclusionMay respond to topical capsaicin [232–234]

Diagnosis of rhinitis

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix


A detailed history is vital for an accurate diagnosis. The patient is asked to list their main symptoms in order of priority and this usually produces a short list of differential diagnoses.


Sneezing, itchy nose, itchy palate. AR is likely and further refinement of the diagnosis is aided by asking whether the symptoms are intermittent or persistent although this is not a substitute for specific allergen testing.

  • Seasonal at the same time each year? – pollens or mould spores.
  • At home? – pets or HDM.
  • At work? – occupational allergens.
  • On holiday? – remission suggests an environmental cause.

Rhinorrhoea. Rhinorrhoea is either anterior or leads to post-nasal drip:

  • Clear – infection unlikely.
  • Unilateral – is uncommon and cerebrospinal fluid (CSF) leak should be excluded [21].
  • Coloured ○ yellow – allergy or infection ○ green – usually infection ○ blood tinged
  • unilateral – tumour, foreign body, nose picking or misapplication of nasal spray
  • bilateral – misapplication of nasal spray, granulomatous disorder, bleeding diathesis or nose picking.
Nasal obstruction
  • Unilateral – usually septal deviation but also consider foreign body, antrochoanal polyp and tumours.
  • Bilateral – may be septal (sigmoid) deviation but more likely rhinitis or nasal polyps.
  • Alternating – generalized rhinitis exposing the nasal cycle [22].
Nasal crusting
  • Severe nasal crusting especially high inside the nose is an unusual symptom and requires further investigation. Consider nose picking, Wegener's granulomatosis, sarcoidosis, other vasculitides, ozaena (wasting away of the bony ridges and mucous membranes inside the nose), non-invasive ventilation and chronic rhinosinusitis [23].
  • Rarely, topical steroids may cause crusting.

Eye symptoms. Eye symptoms associated with AR and particularly with seasonal rhinitis include intense itching, hyperaemia, watering, chemosis and periorbital oedema. Symptoms typically resolve within 24 h if removed from the allergen source.

Other symptoms. Other symptoms such as snoring, sleep problems, repeated sniffing or a nasal intonation of the voice can be caused or exacerbated by nasal obstruction and rhinorrhoea from any cause. In some patients with seasonal allergic rhinitis (SAR), oral allergy syndrome is triggered by ingestion of cross-reacting antigens in some fruits, vegetables and nuts [24].

Lower respiratory tract symptoms
  • Cough, wheeze, being short of breath.

Disorders of the upper and lower respiratory tract often coexist:

  • Most asthmatics have rhinitis – see ‘Co-morbid association’ on rhinitis and asthma.
  • In asthma with aspirin sensitivity – 36–96% have nasal polyps with rhinosinusitis [25].

Family history. A family history of atopy, seasonal rhinitis or asthma makes the diagnosis of AR more likely [26].

Social history. In order to assess possible allergen and irritant exposure, a full history of housing conditions, pets, occupation or schooling and, in young children, feeding details should be obtained.

Drugs. A detailed drug history is vital as drugs such as topical sympathomimetics, α-blockers and other anti-hypertensives as well as aspirin and non-steroidal anti-inflammatory drugs may cause rhinitis symptoms (see Table 4). It is important to enquire about the efficacy of previous treatments for rhinitis and details of how they were used and for how long.

Occupation. Exposure to occupationally related triggers is common and may have to be addressed in order to improve rhinitis symptoms.


Visual assessment
  • Horizontal nasal crease across the dorsum of the nose– supports a diagnosis of AR.
  • Depressed nasal bridge – post-surgery, Wegener's granulomatosis or cocaine misuse.
  • Widened bridge; polyps (see also BSACI guideline on rhinosinusitis and nasal polyposis).
  • Purple tip in lupus pernio due to sarcoidosis.
  • An assessment of nasal airflow – (e.g. metal spatula misting in young children).
Anterior rhinoscopy
  • Appearance of the turbinates.
  • The presence/absence of purulent secretions.
  • The presence/absence of nasal polyps, but it may not be possible to see a small ones. Larger polyps can be seen at the nares and are distinguishable from the inferior turbinate by their lack of sensitivity, yellowish grey colour and the ability to get between them and the side wall of the nose.
  • Yellow sub-mucosal nodules with a cobblestone appearance suggest sarcoidosis [27].
  • Crusting and granulations raise the possibility of vasculitis.
  • Septal perforation may occur after septal surgery, due to chronic vasoconstriction (cocaine, α-agonists), Wegener's granulomatosis, nose picking and very rarely steroid nasal sprays.


Objective measures of nasal airway. Objective measurements of the nasal airway are not made in routine clinical practice but can be useful when allergen or aspirin challenges are undertaken and may be helpful when septal surgery or turbinate reduction are being contemplated.

Peak nasal inspiratory flow. Measurement of peak nasal inspiratory flow provides a simple and inexpensive method for determining nasal airway patency using a nasal inspiratory flow meter. The results are reproducible and correlate with rhinoscopic evidence of rhinitis but not with symptom scores [28]. The technique is most useful for comparing changes in airway patency within the same subject, although some normative data are now available [29].

Acoustic rhinometry. Acoustic rhinometry can be used to measure changes in mucosal congestion using reflected sound. The technique is based on the physical principle that sound in the nasal cavity is reflected by changes in acoustic impedance caused by changes in cavity dimensions. The change in acoustic impedance between the incident wave and reflected sound waves is proportional to the cross-sectional area. The method requires standardization and considerable experience to interpret and obtain reproducible results. Guidelines for its use are published [30].

Rhinomanometry. Rhinomanometry allows an estimation of nasal resistance from pressure–flow relationships and is difficult to perform reproducibly but is still regarded by some as the most accurate measure of nasal airway patency. With anterior rhinomanometry, the pressure sensor is placed at the tip of each nostril and resistance is measured in each nostril separately. With posterior rhinomanometry, the pressure sensor is placed in the back of the nasal cavity and total nasal airway resistance is determined. The technique requires expensive equipment and considerable experience in interpretation [31].

Nasal endoscopy. Used in specialist centres, this is more specific than rhinoscopy and alters the diagnosis in up to a fifth of patients with nasal disease [32].

Allergen-specific immunoglobulin E. Allergen-specific IgE can be detected with SPTs or by a serum immunoassay.

Skin prick tests. SPTs should be carried out routinely in all cases in order to determine whether the rhinitis is allergic or non-allergic. Injectable adrenaline should be available, but is unlikely to be needed.

  • Must be interpreted in the light of the clinical history. At least 15% of people with a positive SPT do not develop symptoms on exposure to the relevant allergen [33].
  • Have a high negative predictive value.
  • Suppressed by antihistamines, tricyclic antidepressants and topical but not oral steroids [34].
  • Are inadvisable outside specialist allergy clinics if the patient has a history of anaphylaxis.

Serum total and specific immunoglobulin E. Serum-specific IgE may be requested when skin tests are not possible or when the SPT, together with the clinical history, give equivocal results.

  • Total IgE alone can be misleading but may aid interpretation of specific IgE.
  • Allergen-specific IgE correlates with the results of SPTs and nasal challenges although there are exceptions.
  • Currently available SPTs and immunoassays show similar sensitivity for HDM, but SPTs are more sensitive to other inhalant allergens such as cat epithelium, mould and grass pollen [35].

Routine laboratory investigations. Other investigations to help with the initial management of patients with rhinitis are guided by the findings from the history, examination and results of SPTs. Examples of routine laboratory investigations include:

  • Full blood count and differential white cell count.
  • C-reactive protein.
  • Nasal smear/brushing for eosinophils.
  • Microbiological examination of sputum and sinus swabs.
  • Nasal secretions – CSF asialotransferrin for CSF rhinorrhoea.
  • Urine toxicology when cocaine abuse is suspected.

Olfactory tests. The University of Pennsylvania Smell Identification Test is well validated, can identify malingerers [36] and is accepted for legal cases.

Cytology. The techniques for obtaining cells for cytology in secretions, lavage, scraping, cotton pledgelets or brushings have not been standardized, nor have the criteria for evaluating cell counts [37]. Nevertheless, the presence of eosinophils implies inflammation and may be helpful in predicting response to corticosteroids.

Exhaled nitric oxide. Exhaled nitric oxide (FeNO, fractional exhaled nitric oxide) measurement can be useful clinically in the diagnosis and monitoring of asthma. Normal levels are <20 p.p.b., but become elevated in eosinophilic lower respiratory tract inflammation [38].

Nasal challenge
  • Is not routinely available outside specialist centres.
  • There is no standardized methodology.
  • Asthmatic reactions can occur.
  • May be useful to confirm aspirin sensitivity.
  • May be useful in patients with an unclear history and negative or equivocal tests for allergen-specific IgE or when the trigger is not IgE mediated.
  • Has a role in occupational AR, where there is a discrepancy between history and when there are potentially important occupational implications.

Tests for asthma. Measurements of lung function should be considered in all patients with persistent rhinitis e.g. peak expiratory flow rate and spirometry as detailed in the British Thoracic Society guidelines on the management of asthma [39].

Treatment of rhinitis

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Figure 3 shows an algorithm for the treatment of rhinitis. Grades of recommendation are given in Table A4.


Figure 3.  Algorithm for the treatment of rhinitis. *Spray or drops. OC, oral corticosteroids; α-H1, antihistamines; LTRA, leukotriene receptor antagonist; Sx, symptoms; Rx, treatment; SPT, skin prick test.

Download figure to PowerPoint


  • Standardized allergy education of health personnel improves disease-specific QOL [40]. (Grade of recommendation=C)
  • The patient or parents of children should be informed about the nature of the disease, causes and mechanisms of rhinitis, the symptoms and available treatments.
  • Education on means of allergen avoidance and drug therapy, including safety and potential side effects, should be provided.
  • Treatment failure may be related to poor technique in the use of nasal sprays and drops and therefore appropriate training is imperative (Figs 4a and b) [41, 42].
  • It is important to provide patients with education on the complications of rhinitis including sinusitis and otitis media, and comorbid conditions such as asthma and nasal polyps. They should be aware of how such complications are recognized and treated.
  • Patients should be made aware of the potential negative impact of rhinitis on their QOL and benefits of complying with therapeutic recommendations.
  • Patients should be provided with realistic expectations for the results of therapy and should understand that complete cures do not usually occur in the treatment of chronic diseases, including rhinitis, and that long-term treatment may be needed.

Figure 4.  (a) Correct procedure for the application of nasal sprays. (b) Correct procedure for the installation of nasal drops.

Download figure to PowerPoint

Allergen avoidance

Allergen avoidance decisions are complicated and the clinician's task of providing advice to patients is not facilitated by the paucity of available evidence. Avoidance is clearly beneficial in allergy to domestic pets, horses and certain occupational allergens (laboratory animals, latex), where clinical trials are unnecessary. However, a number of measures designed to reduce mite exposure have not shown the expected results. The appendix to this document includes several tables providing advice on allergen avoidance (see Tables A1–A3).

House dust mite. HDM is the most common indoor allergen causing rhinitis. It is logical to assume that reduction of allergens such as HDM would reduce symptoms in sensitized patients. However, the evidence to refute or confirm this hypothesis is lacking. Use of mite-proof bed covers as a single intervention in mite-allergic adults or children is not of proven value according to a number of placebo-controlled trials [43, 44]. A Cochrane meta-analysis in 2001 [45] addressed the potential benefit of HDM avoidance measures for perennial allergic rhinitis. It was found that the benefit of using a single measure to improve symptoms of perennial rhinitis was questionable. Efforts to obtain maximal mite elimination may lead to clinical benefits in selected highly motivated patients, and clinical benefits are most likely with multiple interventions [46].

Pollen avoidance in seasonal allergic rhinitis. Nasal filters have been shown to reduce symptoms of AR and allergic conjunctivitis significantly during the ragweed and grass pollen seasons [47]. A number of other measures are often recommended to patients with pollen allergy to minimize symptoms but these are based on expert consensus rather than clinical trial data (Table A2).

Cat allergen. There are no trials examining whether measures to minimize cat allergen levels lead to clinical improvement in rhinitis as it takes several months for cat allergens to disappear from a home once the cat has been removed. Therefore, trials of brief cat removal are ineffective [48]. However, it is likely that cat removal will produce an improvement in symptoms, and a number of measures to minimize cat allergen levels at home are recommended (Table A3).

Occupational allergens. Rhinitis may be induced by workplace exposure to a respiratory sensitizing agent (‘occupational rhinitis’), Table 2. Where pre-existing disease is provoked by an (irritant) occupational agent, it is described as ‘work-exacerbated’ rhinitis. The agents that can give rise to occupational rhinitis, numbering over 300, are the same as those that induce occupational asthma. Particle size is probably important in determining the site of disease. Occupational rhinitis is as much as three times more frequent than occupational asthma but the two conditions frequently occur together [49, 50].

An understanding of those occupations that incur relevant exposures and a detailed history of such exposures and their relationship with the onset and pattern of symptoms are essential for identification of occupational rhinitis. If a diagnosis of occupational rhinitis is established, then avoidance of further exposure to the causative agent may lead to cure. Symptoms caused by continuing exposure may be very difficult to treat.

  • Occupational rhinitis generally precedes, and may be a risk factor for, occupational asthma. The risk of occupational asthma is the highest in the year after the development of occupational rhinitis [49, 51]. (Level of evidence=2−)
  • The early identification of a causative occupational agent and the avoidance of exposure are important measures for the management of occupational rhinitis and prevention of progression to occupational asthma [47, 48, 52, 53]. (Level of evidence=2++; grade of recommendation=B)
  • Prevention of latex allergy by removing powdered gloves or substituting non-latex ones is essential. All healthcare environments should have a latex policy [53, 54]. (Level of evidence=2+ and 4; Grade of recommendation=D, C for adults and children with perennial rhinitis or adults and children with latex allergy.)

Irritant avoidance. Many patients with active rhinitis exhibit nasal hyper-reactivity to substances such as smoke, pollutants, perfume and dust and to temperature change. In many cases, it is likely that improved management of rhinitis will lead to an improvement in symptoms of nasal hyper-reactivity. (Grade of recommendation=D)

Nasal douching and drops

In mainland Europe, nasal douching is a more commonly used therapy than in the United Kingdom. Saline douching reduced symptoms in children and adults with seasonal rhinitis [55, 56] (Grade of recommendation=A). It is a safe, inexpensive treatment.

Adverse events
  • Sodium load should be considered in hypertensive patients.
Place in therapy
  • Additional to therapy in rhinitis.
  • Effective in children with seasonal and other forms of AR in combination with conventional treatment [55, 57].
  • Sterile saline eyedrops are a simple, non-toxic and effective addition for seasonal allergic conjunctivitis [58].


Despite allergen and trigger avoidance, many rhinitis sufferers continue to have persistent symptoms, the nature of which should determine the selection of medication. Available treatments and their effects on individual symptoms are detailed in Table 5. (All have a grade of recommendation=A)

Table 5.   Effect of therapies on rhinitis symptoms (adapted from [235])
 SneezingRhinorrhoeaNasal obstructionNasal itchEye symptoms
 Eye drops0000+++
 Eye drops0000++
Oral H1-antihistamines (Table 6)
Table 6.   Oral antihistamines licensed in the UK according to age
AgeNon-sedating antihistamineSedating antihistamine
  1. SAR, seasonal allergic rhinitis

>6 months Alimemazine (trimeprazine)
>1 yearDesloratadineHydroxyzine hydrochloride
>2 yearsCetirizine hydrochloride (SAR only)Cyproheptadine hydrochloride
LoratadinePromethazine hydrochloride
Levocetirizine hydrochlorideKetotifen
>6 yearsFexofenadine hydrochloride (SAR only) 
Cetirizine hydrochloride 
>12 yearsAcrivastine 
Fexofenadine hydrochloride 
  • Reduce total nasal symptom scores by a mean of 7% (5–9%) more than placebo [59].
  • Effective predominantly on neurally mediated symptoms of itch, sneeze and rhinorrhoea.
  • Desloratadine, fexofenadine, cetirizine and levocetirizine have modest effects on nasal blockage [60–65].
  • Improve allergic symptoms at sites other than the nose such as the conjunctiva, palate, skin and lower airways [66–68].
  • Regular therapy is more effective than ‘as-needed’ use in persistent rhinitis [69].
  • Can significantly improve QOL [70].
Adverse events
  • First-generation antihistamines, e.g. chlorphenamine, diphenhydramine, cause sedation and reduce academic and/or work performance and should be avoided [71, 72].
  • Second-generation antihistamines, e.g. acrivastine, cetirizine, desloratadine, fexofenadine levocetirizine, loratadine and mizolastine are less sedating in most patients, with fexofenadine the least sedating [73, 74]. In addition, they ○ do not cause significant QT prolongation at normal therapeutic doses ○ have few major drug interactions, except for increased risk of ventricular arrhythmias, when mizolastine is co-administered with some anti-arrhythmics, antibiotics and β-blockers.
H1-antihistamines – topical nasal
  • Azelastine − therapeutic effects superior to oral antihistamines for rhinitis symptoms [75, 76].
  • Do not improve symptoms due to histamine at other sites, such as the eye, pharynx, lower airways and skin.
  • Fast onset of action within 15 min [75] – useful as rescue therapy.
Adverse events
  • Local irritation.
  • Taste disturbance with azelastine.
Place in therapy – oral and topical antihistamines
  • First-line therapy for mild to moderate intermittent and mild persistent rhinitis.
  • Additional to intranasal steroids for moderate/severe persistent rhinitis uncontrolled on topical intranasal corticosteroids alone [77–79].
Topical intranasal corticosteroids
  • Meta-analysis shows that intranasal corticosteroids (INS) are superior to antihistamines [80, 81].
  • Act by suppression of inflammation at multiple points in the inflammatory cascade [82].
  • Reduce all symptoms of rhinitis by about 17% greater than placebo, with a variable effect on associated allergic conjunctivitis [59].
  • Onset of action is 6–8 h after the first dose, clinical improvement may not be apparent for a few days and maximal effect may not be apparent until after 2 weeks [81].
  • Starting treatment 2 weeks before a known allergen season improves efficacy [83].
  • Similar clinical efficacy for all INS but bioavailability varies considerably.
  • Systemic absorption negligible with mometasone and fluticasone, modest for the remainder and high for betamethasone and dexamethasone – these should be used short term only [84–86].
  • Long-term growth studies in children using fluticasone, mometasone and budesonide have reassuring safety data, unlike beclomethasone [87–91].
  • Concomitant treatment with CYP3A inhibitors such as itraconazole or ritonivir may increase systemic bioavailability of intranasal corticosteroids [92, 93].
Adverse events
  • Local nasal irritation, sore throat and epistaxis affect around 10% of users.
  • Benzalkonium chloride is used as a preservative in all topical corticosteroids, except Rhinocort® (Astrazeneca International, London, UK) nasal spray and Flixonase® nasules, and may irritate the nose, but does not adversely affect mucociliary clearance [94].
  • Reduction of local adverse effects can probably be achieved by correct use; see Fig. 4a. (Grade of recommendation=D)
  • Nasal drops are useful for severe obstruction and should be used in the ‘head upside down’ position in order to reach the ostiomeatal complex; see Fig. 4b.
  • Hypothalmic–pituitary axis suppression may occur when multiple sites are treated with topical corticosteroids in the same person (e.g. skin, nose and chest). It is advisable to monitor growth in children [95] (see also Table 7).
  • Raised intra-ocular pressure has been described with INS [96], and patients with a history of glaucoma should be monitored more closely.
Table 7.   Nasal corticosteroids licensed for use in the United Kingdom according to age
Age (years)DrugGood safety dataAvailability
>4Fluticasone proprionate sprayYesOver the counter
>5FlunisolidePrescription only
Dexamethasone isonicotinate with Tramazoline hydrochloridePrescription only
>6Mometasone furoateYesPrescription only
Triamcinolone acetonidePrescription only
Beclomethasone diproprionate Over the counter
>12BudesonideYesPrescription only
BetamethasonePrescription only
Place in therapy
  • First-line therapy for moderate to severe persistent symptoms and treatment failures with antihistamines alone [18, 81].
  • Topical steroid drops should be used initially in nasal polyposis and severe obstruction.
Systemic glucocorticosteroids
  • Rarely indicated in the management of rhinitis, except for: ○ severe nasal obstruction ○ short-term rescue medication for uncontrolled symptoms on conventional pharmacotherapy ○ important social or work-related events, e.g. examinations, weddings
  • Oral corticosteroids should be used briefly and always in combination with a topical nasal corticosteroid. A suggested regime for adults is 0.5 mg/kg given orally in the morning with food for 5–10 days.
Injectable corticosteroids
  • Injected preparations are not recommended unless under exceptional circumstances [97, 98].
  • Compared with other available treatments, the risk–benefit profile for intramuscular corticosteroids is poor [97].
  • Anti-leukotrienes are of two kinds: (i) receptor antagonists (LTRAs, e.g. montelukast and zafirlukast) [99] and (ii) synthesis inhibitors, e.g. zileuton (unavailable in the United Kingdom).
  • There is a spectrum of individual responsiveness to LTRAs that is currently not predictable [100–102].
  • Therapeutic profile similar to antihistamines, with efficacy comparable to loratadine in SAR [103]. However, the response is less consistent than that observed with antihistamines. A study found that LTRAs reduced the mean daily rhinitis symptom scores by 5% more than placebo [59].
  • Anti-leukotrienes are less effective than topical nasal corticosteroids [103–106].
  • Anti-leukotriene plus antihistamine combinations do not improve efficacy to a clinically relevant extent compared with either drug used alone [107–110], and their use in rhinitis is thus disputed [111].
  • The combination of antihistamine and anti-leukotriene is no more effective than topical corticosteroid alone [112, 113].
  • May have a place in patients with SAR and asthma [114].
Adverse events
  • Usually well tolerated; occasional headache, gastrointestinal symptoms or rashes.
  • Occasional reports of Churg–Strauss syndrome that may relate more to steroid withdrawal rather than a direct effect of the drug, although further long-term evaluation is needed.
Place in therapy
  • Montelukast is licensed in the United Kingdom for those with SAR who also have concomitant asthma (UK license for age >6 months; Zafirlukast UK license >12 years).
  • May be useful in patients with asthma and persistent rhinitis.
  • Some patients with aspirin sensitivity appear to show marked improvement [115], although at present, it is not possible to predict responders other than by use of a trial of therapy.
Topical anti-cholinergic: ipratropium bromide (Rinatec®, Boehringer Ingelheim Ltd., Berkshire, UK)
  • Decreases rhinorrhoea but has no effect on other nasal symptoms [116–118].
  • Needs to be used three times daily, mainly in the morning, e.g. before breakfast, after breakfast and after morning tea break (symptoms of rhinorrhoea occur mainly in the morning).
  • Regular use may be effective, particularly: ○In ‘old man's drip’ ○ As an ‘add on’ for AR when watery rhinorrhoea persists despite topical steroids and antihistamines ○ For autonomic rhinitis when the dominant symptom is profuse watery rhinorrhoea in response to irritant triggers or changes in temperature [119, 120]
  • Also useful in the common cold.
Adverse events
  • Dry nose and epistaxis [121].
  • Systemic anti-cholinergic effects are unusual [122] ○ Urinary retention [123] ○ Glaucoma [124]
  • Caution advised in the elderly.
Place in therapy
  • Autonomic rhinitis.
  • Persistent rhinorrhoea from other causes.

Intranasal decongestants. The α1-agonist ephedrine (as nasal drops) and α2-agonist xylometazoline (available as nasal drops or spray for adults and children over 3 months of age) are sympathomimetics that increase nasal vasoconstriction and are effective for nasal obstruction in both allergic and non-AR [125]. Oxymetazoline has an action that starts within 10 min and lasts up to 12 h.

Adverse events
  • Regular use can lead to rhinitis medicamentosa with tachyphylaxis to the drug and marked chronic nasal obstruction [126].
  • Nasal irritation.
  • May increase rhinorrhoea.
Place in therapy
  • Brief use of <10 days is advised in order to avoid rebound effect ○ for eustachian tube dysfunction when flying ○ in children with acute otitis media to relieve middle ear pain/pressure ○ post-URTI to reduce nasal/sinus congestion ○ to increase nasal patency before intranasal administration of nasal steroids
Oral decongestants (pseudoephedrine)
  • Weakly effective in reducing nasal obstruction [127].
  • Do not cause a rebound effect on withdrawal but are less effective than topical preparations for nasal obstruction [128].
  • Effect lasts 30 min – 6 h or longer with slow-release preparations.
  • Hypertension
  • Interact with antidepressants
  • Insomnia
  • Agitation
  • Tachycardia
Place in therapy
  • Not generally recommended.

Chromones [sodium cromoglicate (=cromolyn) and nedocromil sodium]. Sodium cromoglicate and nedocromil sodium inhibit the degranulation of sensitized mast cells, inhibiting the release of inflammatory and allergic mediators [129]. Sodium cromoglicate is weakly effective in rhinitis, with some effect on nasal obstruction [130, 131]. The spray needs to be used several times (three to four) per day.

Adverse events

  • Local irritation
  • Rarely transient bronchospasm
  • Occasional taste perversion
  • Headache
Place in therapy

Generally very well tolerated (pregnancy)

  • Children and adults with mild symptoms only and sporadic problems in season or on limited exposure [132].
  • Cromoglicate and nedocromil eyedrops are useful in conjunctivitis as topical therapy [133, 134].

Allergen immunotherapy

Allergen immunotherapy involves the repeated administration of an allergen extract in order to reduce symptoms and the need for rescue medication on subsequent exposure to that allergen [135]. Immunotherapy can be highly effective and is the only treatment that is able to modify the natural history of AR and offer the potential for long-term disease remission [136, 137] (level of evidence=1+). Recent reviews include the ‘ARIA Update’ [138] and ‘Standards for Practical Immunotherapy’ (European guideline) [139].

Whereas non-sedating anti-histamines and topical nasal corticosteroids remain first-line treatments for AR, immunotherapy is recommended in those subjects with IgE-mediated disease in whom allergen avoidance is either undesirable or not feasible and who fail to respond to optimal treatment [18]. The benefit to risk ratio should be considered in every case. The quality of allergen vaccines is important and only standardized extracts should be used. An optimal maintenance dose of 5–20 μg of major allergen per maintenance injection has been shown to correspond with clinical efficacy [135].

Adverse events
  • Pain and swelling at the site of injection is seen in the majority of patients.
  • Systemic reactions (particularly in patients with asthma [140]): including urticaria, angio-oedema, asthma and anaphylaxis.
  • Chronic asthma is a contraindication in the United Kingdom [141].

For these reasons, immunotherapy should only be performed:

  • under the supervision of a physician fully trained in the management of allergic disease
  • with immediate access to adrenaline and other resuscitative measures
  • patients should be observed for a minimum of 60 min (30 min in mainland Europe) following injections [141, 142]

Place in therapy

At present, within the United Kingdom, allergen injection immunotherapy is recommended in patients with:

  • IgE-mediated seasonal pollen-induced rhinitis and/or conjunctivitis in patients whose symptoms respond inadequately to usual therapy [143, 144]. (Level evidence=1+; Grade of recommendation=A)
  • persistent symptoms despite a trial of medical therapy in carefully selected patients with an allergy to animals (e.g. cat) or HDM and where the allergen is not easily avoided e.g. occupational allergy in vets or public sector workers.
  • systemic allergic reactions to stinging insect venom (wasp or bee).

Sublingual immunotherapy

SLIT has been proposed as an alternative to the subcutaneous route [145]. SLIT has been shown to be effective in both rhinitis and asthmatic patients and to have a good safety profile (no anaphylactic reactions reported) [145, 146]. A recent Cochrane meta-analysis [147] concluded that ‘SLIT is a safe treatment which significantly reduces symptoms and medication requirements in AR. The size of the benefit compared with that of other available therapies, particularly injection immunotherapy, is not clear, having been assessed directly in very few studies. Further research is required concentrating on optimizing allergen dosage and patient selection’.

Recent studies performed in large samples of patients have shown a clear dose effect of tablet-based SLIT in patients with grass pollen-induced rhinoconjunctivitis [148–150]. In one study in which subcutaneous and SLIT for seasonal rhinitis were compared, both were effective compared with placebo, although the study was underpowered to detect differences between treatments [151]. A further recent trial of grass allergen tablets for sublingual use demonstrated a 30–40% improvement in symptom and medication scores and an approximate 50% increase in the responder rate, compared with placebo [152]. A further follow-up for 5 years is planned in order to assess possible long-term benefits of SLIT as has already been confirmed for the subcutaneous route.

Anti-immunoglobulin E

At present, this is only licensed for severe allergic asthma in patients over 12 years of age. It is likely that associated AR would also improve in patients who respond with an improvement in their asthma control. Future use may include combined treatment with immunotherapy in high-risk patients.


Surgery is required only for a small minority of cases. Indications for surgical intervention are:

  • Drug-resistant inferior turbinate hypertrophy [153].
  • Anatomical variations of the septum with functional relevance.
  • Anatomical variations of the bony pyramid with functional relevance.

Rhinitis and pregnancy

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Rhinitis affects at least 20% of pregnancies [154] and can start during any gestational week [155]. Although the pathogenesis is multifactorial, nasal vascular engorgement and placental growth hormone are likely to be involved [155, 156]. Informing the patient that pregnancy-induced rhinitis is a self-limiting condition is often reassuring.

Most medications cross the placenta, and should only be prescribed when the apparent benefit is greater than the risk to the foetus [157]. Regular nasal douching may be helpful. It is a good practice to start treatment with ‘tried and tested’ drugs [157]. Beclomethasone, fluticasone and budesonide appear to have good safety records as they are widely used in pregnant asthmatic women [158–160]. Chlorphenamine, loratadine and cetirizine may be added but decongestants should be avoided [161, 162]. Chromones have not shown teratogenic effects in animals and are the safest drug recommended in the first 3 months of pregnancy although they require multiple daily administrations. Patients already on immunotherapy may continue if they have already reached the maintenance phase but each case must be considered individually. However, initiation of immunotherapy and updosing is contraindicated [154].

Co-morbid association

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Rhinitis and asthma – the link

Rhinitis and asthma are common diseases associated with substantial cost to patients, employers and health care systems. Asthma and rhinitis usually co-exist [163–168], with symptoms of rhinitis found in 75–80% of patients with asthma [163, 169]. Although the costs of rhinitis and asthma are independently high, medical care costs are higher in those with asthma and rhinitis compared with those with asthma alone [164].

Rhinitis is a risk factor for the development of asthma [165]. A number of allergens affect both the nose and the lungs [163] and allergy to HDM or cat dander is a risk factor for both asthma and rhinitis [170, 171]. Many patients with AR have increased non-specific bronchial reactivity [172, 173] during seasonal [174] and perennial [175] allergen exposure. Asthma [169] and bronchial hyperresponsiveness are more common and severe in perennial compared with seasonal rhinitis [175, 176]. Patients with SAR develop seasonal increases in non-specific bronchial responsiveness (BR) but not necessarily asthma symptoms, and these patients often have normal BR during the winter months [177]. BR is also increased in viral rhinitis [178, 179] and following nasal allergen challenge [180, 181]. These observations suggest that bronchial inflammation is associated with nasal inflammation, and is supported by the fact that bronchial hyper-reactivity is reversed by intranasal treatment with sodium cromoglycate [182] and corticosteroids [38, 183]. Nasal allergen challenge results in eosinophil ingress not only to the nose but also to the bronchi, and vice versa [184]. Segmental bronchoprovocation with allergen in AR patients leads to significant changes in mast cell and basophil numbers in both the nasal and bronchial mucosa [185]. A systemic link has been postulated with inhaled allergen, causing a release of immature eosinophils from the bone marrow into the circulation, from where they migrate to the whole respiratory tract, not just to the site of allergen contact [186].

Allergen-specific immunotherapy for rhinitis has been shown to reduce the development of asthma in children [137] and to reduce non-specific bronchial hyper-reactivity and seasonal asthma in adults with seasonal rhinoconjunctivitis [177]. Patients with co-morbid asthma and rhinitis who are receiving treatment for AR have a significantly lower risk of hospitalizations or attending accident and emergency departments for asthma [187–191].

Allergic rhinitis in children

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Selection of treatment should be considered in the context of the child's needs and response to a given agent. Adherence issues are important because treatment is given chronically. It is essential to explain treatment options to parents [192].

First-line treatments

Antihistamines. Compliance with once-daily administration of a long-acting antihistamine is likely to be better than medication that requires multiple daily doses. Antihistamines are useful if the main symptoms are rhinorrhoea and sneezing, or if there are symptoms outside the nose such as conjunctivitis or rash. Desloratadine, cetirizine, levocetirizine and fexofenadine may also be beneficial for symptoms of nasal congestion [60, 61, 64, 65, 193]. For optimal results, they should be given continuously or prophylactically as opposed to ‘as required’ [194].

Nasal steroids. Nasal steroid with low systemic bioavailability should be used at the lowest possible dose to control symptoms and are useful for nasal congestion and obstruction. Intermittent use may be beneficial due to the rapid vasoconstrictor effect of corticosteroids [195, 196]. Compliance and efficacy is improved if the child is taught how to use the nasal spray, Fig. 4a [41].

Second-line treatments

  • For relief of nasal congestion, short-term use (<14 days) of corticosteroid nose drops (e.g. betamethasone or fluticasone) and a topical decongestant may be helpful [197]. The best position for administration of nose drops is with the child lying, head back; see Fig. 4b [42]. A short course of oral steroids may be required to relieve nasal congestion with systemic symptoms in SAR. Surgical referral for submucosal resection of the inferior turbinate bones may be indicated only if extensive medical treatment fails [153].
  • For refractory rhinorrhoea, ipratropium bromide 0.03% may be helpful [120, 198].
  • For SAR, saline nasal irrigation during the pollen season may improve symptoms and reduce antihistamine requirement [55].
  • Leukotriene receptor antagonists may have a role if there is concomitant asthma [103].
  • To treat underlying allergic disease, allergen immunotherapy is widely used in Europe but has yet to gain general acceptance in the United Kingdom [136, 137]. Efficacy has been demonstrated with both subcutaneous [137, 199] and SLIT [200–203] but is contra-indicated in children with asthma.

Future research

  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix
  • SLIT, its safety, long-term effectiveness and ability to reduce disease progression.
  • Utility of anti-IgE therapy in conjuction with specific immunotherapy.
  • Value of extensive, multi-allergen avoidance measures – particularly HDM.
  • Aetiological factors that can be altered to reduce the incidence of rhinitis.
  • Prospective study examining whether early identification and effective therapy for rhinitis in children reduces progression to asthma.
  • Prospective study examining whether effective therapy for rhinitis reduces asthma exacerbations and cost.

These guidelines inform the management of allergic and non-AR. Adherence to these guidelines does not constitute an automatic defence for negligence and conversely non-adherence is not indicative of negligence. It is anticipated that these guidelines will be reviewed 5 yearly.


  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

The preparation of this document has benefited from extensive discussions within the SOCC of the BSACI and we would like to acknowledge all the members of this committee for their valuable contribution namely, Pierre Dugué, Pamela Ewan, Pia Huber, Nasreen Khan, Ian Pollock, Richard Powell and Angela Simpson. We would like to thank Cate Barrington-Ward for drawing Fig. 4a. Finally, we would like to acknowledge the very valuable considerations and criticism we received from many BSACI members during the consultation process.


  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix
  • 1
    Laforest L, Bousquet J, Pietri G et al. Quality of life during pollen season in patients with seasonal allergic rhinitis with or without asthma. Int Arch Allergy Immunol 2005; 136:2816.
  • 2
    Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004; 20:193752.
  • 3
    Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41:94853.
  • 4
    Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000; 21:713.
  • 5
    Slavin RG. Complications of allergic rhinitis: implications for sinusitis and asthma. J Allergy Clin Immunol 1998; 101:S35760.
  • 6
    Doyle WJ. The link between allergic rhinitis and otitis media. Curr Opin Allergy Clin Immunol 2002; 2:215.
  • 7
    Passalacqua G, Ciprandi G, Pasquali M, Guerra L, Canonica GW. An update on the asthma–rhinitis link. Curr Opin Allergy Clin Immunol 2004; 4:17783.
  • 8
    Barry B. Rhino-sinus manifestations of systemic diseases. Rev Prat 2000; 50:154850.
  • 9
    Powell RJ, Du Toit GL, Siddique N et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:63150.
  • 10
    Aberg N, Hesselmar B, Aberg B, Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin Exp Allergy 1995; 25:8159.
  • 11
    Maziak W, Behrens T, Brasky TM et al. Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Munster, Germany. Allergy 2003; 58:5729.
  • 12
    Kaiser HB. Risk factors in allergy/asthma. Allergy Asthma Proc 2004; 25:710.
  • 13
    D'Amato G, Liccardi G, D'Amato M, Cazzola M. The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy. Respir Med 2001; 95:60611.
  • 14
    Peden DB. Effect of pollutants in rhinitis. Curr Allergy Asthma Rep 2001; 1:2426.
  • 15
    Park YJ, Baraniuk JN. Mechanisms of allergic rhinitis. Clin Allergy Immunol 2002; 16:27593.
  • 16
    Smurthwaite L, Durham SR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002; 2:2318.
  • 17
    Hansen I, Klimek L, Mosges R, Hormann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004; 4:15963.
  • 18
    Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147334.
  • 19
    Demoly P, Allaert FA, Lecasble M, Bousquet J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003; 58:6725.
  • 20
    Bachert C, Vignola AM, Gevaert P, Leynaert B, Van CP, Bousquet J. Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am 2004; 24:1943.
  • 21
    Marshall AH, Jones NS, Robertson IJ. CSF rhinorrhoea: the place of endoscopic sinus surgery. Br J Neurosurg 2001; 15:812.
  • 22
    Flanagan P, Eccles R. Spontaneous changes of unilateral nasal airflow in man. A re-examination of the ‘nasal cycle’. Acta Otolaryngol 1997; 117:5905.
  • 23
    Jennings CR, Jones NS, Dugar J, Powell RJ, Lowe J. Wegener's granulomatosis – a review of diagnosis and treatment in 53 subjects. Rhinology 1998; 36:18891.
  • 24
    Ortolani C, Ispano M, Pastorello E, Bigi A, Ansaloni R. The oral allergy syndrome. Ann Allergy 1988; 61:4752.
  • 25
    Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol 1977; 59:1721.
  • 26
    Van Arsdel PP Jr, Motulsky AG. Frequency and hereditability of asthma and allergic rhinitis in college students. Acta Genet Stat Med 1959; 9:10114.
  • 27
    Fergie N, Jones NS, Havlat MF. The nasal manifestations of sarcoidosis: a review and report of eight cases. J Laryngol Otol 1999; 113:8938.
  • 28
    Starling-Schwanz R, Peake HL, Salome CM et al. Repeatability of peak nasal inspiratory flow measurements and utility for assessing the severity of rhinitis. Allergy 2005; 60:795800.
  • 29
    Ottaviano G, Scadding GK, Coles S, Lund VJ. Peak nasal inspiratory flow; normal range in adult population. Rhinology 2006; 44:325.
  • 30
    Hilberg O, Pedersen OF. Acoustic rhinometry: recommendations for technical specifications and standard operating procedures. Rhinoloy 2000; 16 (Suppl.):317.
  • 31
    Clement PA. Committee report on standardization of rhinomanometry. Rhinology 1984; 22:1515.
  • 32
    Hughes RG, Jones NS. The role of nasal endoscopy in outpatient management. Clin Otolaryngol Allied Sci 1998; 23:2246.
  • 33
    Droste JH, Kerhof M, De Monchy JG, Schouten JP, Rijcken B. Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study. The Dutch ECRHS Group. J Allergy Clin Immunol 1996; 97:92232.
  • 34
    Taborda-Barata L, Jacobson M, Walker S et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clin Exp Allergy 1996; 26:6878.
  • 35
    Gleeson M, Cripps AW, Hensley MJ, Wlodarczyk JH, Henry RL, Clancy RL. A clinical evaluation in children of the Pharmacia ImmunoCAP system for inhalant allergens. Clin Exp Allergy 1996; 26:697702.
  • 36
    Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984; 94:1768.
  • 37
    Romero JN, Scadding G. Eosinophilia in nasal secretions compared to skin prick test and nasal challenge test in the diagnosis of nasal allergy. Rhinology 1992; 30:16975.
  • 38
    Prieto L, Berto JM, Gutierrez V, Tornero C. Effect of inhaled budesonide on seasonal changes in sensitivity and maximal response to methacholine in pollen-sensitive asthmatic subjects. Eur Respir J 1994; 7:184551.
  • 39
    British Thoracic Society. British guideline on the management of asthma. Thorax 2003; 58 (Suppl. 1):i194.
  • 40
    Sheikh A, Khan-Wasti S, Price D, Smeeth L, Fletcher M, Walker S. Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial. Clin Exp Allergy 2007; 37:909.
  • 41
    Gani F, Pozzi E, Crivellaro MA et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy 2001; 56:658.
  • 42
    Kayarkar R, Clifton NJ, Woolford TJ. An evaluation of the best head position for instillation of steroid nose drops. Clin Otolaryngol Allied Sci 2002; 27:1821.
  • 43
    Recer GM. A review of the effects of impermeable bedding encasements on dust-mite allergen exposure and bronchial hyper-responsiveness in dust-mite-sensitized patients. Clin Exp Allergy 2004; 34:26875.
  • 44
    Terreehorst I, Hak E, Oosting AJ et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003; 349:23746.
  • 45
    Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2001; CD001563.
  • 46
    Eggleston PA, Butz A, Rand C et al. Home environmental intervention in inner-city asthma: a randomized controlled clinical trial. Ann Allergy Asthma Immunol 2005; 95:51824.
  • 47
    O'Meara TJ, Sercombe JK, Morgan G, Reddel HK, Xuan W, Tovey ER. The reduction of rhinitis symptoms by nasal filters during natural exposure to ragweed and grass pollen. Allergy 2005; 60:52932.
  • 48
    Colloff MJ, Ayres J, Carswell F et al. The control of allergens of dust mites and domestic pets: a position paper. Clin Exp Allergy 1992; 22 (Suppl. 2):128.
  • 49
    Karjalainen A, Martikainen R, Klaukka T, Saarinen K, Uitti J. Risk of asthma among Finnish patients with occupational rhinitis. Chest 2003; 123:2838.
  • 50
    Siracusa A, Desrosiers M, Marabini A. Epidemiology of occupational rhinitis: prevalence, aetiology and determinants. Clin Exp Allergy 2000; 30:151934.
  • 51
    Cortona G, Pisati G, Dellabianca A, Moscato G. Respiratory occupational allergies: the experience of the hospital operative unit of occupational medicine in Lombardy from 1990 to 1998. G Ital Med Lav Ergon 2001; 23:6470.
  • 52
    Kronqvist M, Johansson E, Pershagen G, Johansson SG, Van Hage-Hamsten M. Risk factors associated with asthma and rhinoconjunctivitis among Swedish farmers. Allergy 1999; 54:11429.
  • 53
    Filon FL, Radman G. Latex allergy: a follow up study of 1040 healthcare workers. Occup Environ Med 2006; 63:1215.
  • 54
    Hemery ML, Dhivert-Donnadieu H, Verdier R, Dujols P, Godard P, Demoly P. A clinical and serological follow-up study of health care workers allergic to natural rubber latex who had followed a latex avoidance programme. Allergy 2004; 59:10134.
  • 55
    Garavello W, Romagnoli M, Sordo L, Gaini RM, Di BC, Angrisano A. Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: a randomized study. Pediatr Allergy Immunol 2003; 14:1403.
  • 56
    Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:118993.
  • 57
    Garavello W, Di BF, Romagnoli M, Sambataro G, Gaini RM. Nasal rinsing with hypertonic solution: an adjunctive treatment for pediatric seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol 2005; 137:3104.
  • 58
    Joss JD, Craig TJ. Seasonal allergic conjunctivitis: overview and treatment update. J Am Osteopath Assoc 1999; 99:S138.
  • 59
    Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116:33844.
  • 60
    Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56:107780.
  • 61
    Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56:106870.
  • 62
    Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 2004; 34:95864.
  • 63
    Van SJ, Clement PA, Beel MH. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002; 57:34650.
  • 64
    Patou J, De SH, Van CP, Bachert C. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy 2006; 36:97281.
  • 65
    Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007; 62:35966.
  • 66
    Schwarzer G, Bassler D, Mitra A, Ducharme FM, Forster J. Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. Cochrane Database Syst Rev 2004; CD001384.
  • 67
    Portnoy JM, Dinakar C. Review of cetirizine hydrochloride for the treatment of allergic disorders. Expert Opin Pharmacother 2004; 5:12535.
  • 68
    Nelson HS. Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003; 112:S96100.
  • 69
    Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32:48998.
  • 70
    Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114:83844.
  • 71
    Vuurman EF, Van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71:1216.
  • 72
    Sheikh A, Khan-Wasti S, Price D, Smeeth L, Fletcher M, Walker S. Structured allergy training for health professionals improves quality of life in patients with perennial rhinitis: randomised controlled trial. J Allergy Clin Immunol 2005; 115 (Suppl.):S42.
  • 73
    Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32:1339.
  • 74
    Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:92733.
  • 75
    McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs 1998; 56:91114.
  • 76
    Portnoy JM, Van OT, Williams PB. Evidence-based strategies for treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004; 4:43946.
  • 77
    Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989; 83:62733.
  • 78
    Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994; 73:497502.
  • 79
    Ratner PH, Van Bavel JH, Martin BG et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47:11825.
  • 80
    Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89:47984.
  • 81
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317:16249.
  • 82
    Fokkens WJ, Godthelp T, Holm AF, Klein-Jan A. Local corticosteroid treatment: the effect on cells and cytokines in nasal allergic inflammation. Am J Rhinol 1998; 12:216.
  • 83
    Graft D, Aaronson D, Chervinsky P et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996; 98:72431.
  • 84
    Homer JJ, Gazis TG. Cushing's syndrome induced by betamethasone nose drops. In rhinological disease betamethasone should be regarded as systemic corticosteroid. BMJ 1999; 318:1355.
  • 85
    Perry RJ, Findlay CA, Donaldson MD. Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 2002; 87:458.
  • 86
    Fowler PD, Gazis AG, Page SR, Jones NS. A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo–pituitary–adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci 2002; 27:48993.
  • 87
    Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000; 106:S17990.
  • 88
    Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003; 26:86393.
  • 89
    Moller C, Ahlstrom H, Henricson KA, Malmqvist LA, Akerlund A, Hildebrand H. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003; 33:81622.
  • 90
    Schenkel EJ, Skoner DP, Bronsky EA et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105:E22.
  • 91
    Skoner DP, Rachelefsky GS, Meltzer EO et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000; 105:E23.
  • 92
    Johnson SR, Marion AA, Vrchoticky T, Emmanuel PJ, Lujan-Zilbermann J. Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr 2006; 148:3868.
  • 93
    Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20:12733.
  • 94
    McMahon C, Darby Y, Ryan R, Scadding G. Immediate and short-term effects of benzalkonium chloride on the human nasal mucosa in vivo. Clin Otolaryngol Allied Sci 1997; 22:31822.
  • 95
    Allen DB, Meltzer EO, Lemanske RF Jr et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23:40713.
  • 96
    Bui CM, Chen H, Shyr Y, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005; 116:10427.
  • 97
    Nasser SM, Ewan PW. Lesson of the week: depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. BMJ 2001; 322:158991.
  • 98
    Anonymous. Any place for depot triamcinolone in hay fever?. Drug Ther Bull 1999; 37:178.
  • 99
    Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16:28997.
  • 100
    Fowler SJ, Hall IP, Wilson AM, Wheatley AP, Lipworth BJ. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002; 58:18790.
  • 101
    Sampson AP, Siddiqui S, Buchanan D et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 (Suppl. 2):S2831.
  • 102
    Mastalerz L, Nizankowska E, Sanak M et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002; 32:94955.
  • 103
    Philip G, Malmstrom K, Hampel FC et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32:10208.
  • 104
    Pullerits T, Praks L, Skoogh BE, Ani R, Lotvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999; 159:18148.
  • 105
    Ratner PH, Howland WC III, Arastu R et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003; 90:53642.
  • 106
    Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31:61624.
  • 107
    Meltzer EO, Malmstrom K, Lu S et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105:91722.
  • 108
    Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88:592600.
  • 109
    Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001; 31:618.
  • 110
    Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32:12632.
  • 111
    Pawankar R. Exploring the role of leukotriene receptor antagonists in the management of allergic rhinitis and comorbid asthma. Clin Exp Allergy Rev 2003; 3:7480.
  • 112
    Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:94955.
  • 113
    Di Lorenzo G., Pacor ML, Pellitteri ME et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004; 34:25967.
  • 114
    Philip G, Nayak AS, Berger WE et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20:154958.
  • 115
    Dahlen B, Nizankowska E, Szczeklik A et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:118794.
  • 116
    Grossman J, Banov C, Boggs P et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol 1995; 95:11237.
  • 117
    Kaiser HB, Findlay SR, Georgitis JW et al. The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated with perennial allergic rhinitis. Allergy Asthma Proc 1998; 19:239.
  • 118
    Tan R, Corren J. Optimum treatment of rhinitis in the elderly. Drugs Aging 1995; 7:16875.
  • 119
    Ostberg B, Winther B, Borum P, Mygind N. Common cold and high-dose ipratropium bromide: use of anticholinergic medication as an indicator of reflex-mediated hypersecretion. Rhinology 1997; 35:5862.
  • 120
    Bonadonna P, Senna G, Zanon P et al. Cold-induced rhinitis in skiers – clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial. Am J Rhinol 2001; 15:297301.
  • 121
    Wood CC, Fireman P, Grossman J, Wecker M, MacGregor T. Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol 1995; 95:11116.
  • 122
    Bronsky EA, Druce H, Findlay SR et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol 1995; 95:111722.
  • 123
    Pras E, Stienlauf S, Pinkhas J, Sidi Y. Urinary retention associated with ipratropium bromide. Drug Intell Clin Pharmacy 1991; 25:93940.
  • 124
    Hall SK. Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department. Ann Emerg Med 1994; 23:8847.
  • 125
    Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol 2004; 114:S14653.
  • 126
    Scadding GK. Rhinitis medicamentosa. Clin Exp Allergy 1995; 25:3914.
  • 127
    Malm L. Pharmacological background to decongesting and anti-inflammatory treatment of rhinitis and sinusitis. Acta Otolaryngol 1994; 515 (Suppl.):535.
  • 128
    Naclerio RM. Optimizing treatment options. Clin Exp Allergy 1998; 28 (Suppl. 6):549.
  • 129
    Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 2002; 77:3504.
  • 130
    James IG, Campbell LM, Harrison JM, Fell PJ, Ellers-Lenz B, Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003; 19:31320.
  • 131
    Meltzer EO. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther 2002; 24:94252.
  • 132
    Hadley JA. Cost-effective pharmacotherapy for inhalant allergic rhinitis. Otolaryngol Clin North Am 2003; 36:82536.
  • 133
    James IG, Campbell LM, Harrison JM, Fell PJ, Ellers-Lenz B, Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003; 19:31320.
  • 134
    Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004; 54:4516.
  • 135
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:55862.
  • 136
    Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:46875.
  • 137
    Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:2516.
  • 138
    Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119:88191.
  • 139
    Alvarez-Cuesta O, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 (Suppl. 82):120.
  • 140
    Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993; 92:615.
  • 141
    Medicines Control Agency Committee on Safety of Medicines. Desensitising vaccines: new advice. Curr Probl Pharmacovigilance 1994; 20:5.
  • 142
    Youlten LJ, Atkinson BA, Lee TH. The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy 1995; 25:15965.
  • 143
    Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. BMJ 1993; 307:91923.
  • 144
    Malling HJ. Immunotherapy in Europe. Clin Exp Allergy 1994; 24:51521.
  • 145
    Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:43748.
  • 146
    Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:56571.
  • 147
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:412.
  • 148
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:8029.
  • 149
    Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:18590.
  • 150
    Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59:4553.
  • 151
    Didier A, Melac M, Combebias A, Andre C. Efficacy and safety of sublingual immunotherapy (slit) tablets in patients with grass pollen rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:721.
  • 152
    Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:43440.
  • 153
    Passali D, Passali FM, Damiani V, Passali GC, Bellussi L. Treatment of inferior turbinate hypertrophy: a randomized clinical trial. Ann Otol Rhinol Laryngol 2003; 112:6838.
  • 154
    Keles N. Treatment of allergic rhinitis during pregnancy. Am J Rhinol 2004; 18:238.
  • 155
    Ellegard EK. The etiology and management of pregnancy rhinitis. Am J Respir Med 2003; 2:46975.
  • 156
    Incaudo GA. Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation. Clin Rev Allergy Immunol 2004; 27:15977.
  • 157
    Gani F, Braida A, Lombardi C, Del GA, Senna GE, Passalacqua G. Rhinitis in pregnancy. Allerg Immunol (Paris) 2003; 35:30613.
  • 158
    Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs 2003; 63:181320.
  • 159
    Ellegard EK, Hellgren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol Allied Sci 2001; 26:394400.
  • 160
    Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf 1999; 20:36175.
  • 161
    Diav-Citrin O, Shechtman S, Aharonovich A et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111:123943.
  • 162
    Moretti ME, Caprara D, Coutinho CJ et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111:47983.
  • 163
    Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991; 46:895901.
  • 164
    Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999; 103:549.
  • 165
    Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994; 94:895901.
  • 166
    Neukirch F, Pin I, Knani J et al. Prevalence of asthma and asthma-like symptoms in three French cities. Respir Med 1995; 89:68592.
  • 167
    Huovinen E, Kaprio J, Laitinen LA, Koskenvuo M. Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and their relation to hay fever and chronic bronchitis. Chest 1999; 115:92836.
  • 168
    Greisner WA III, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998; 19:1858.
  • 169
    Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104:3014.
  • 170
    Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 1989; 19:41924.
  • 171
    Yssel H, Abbal C, Pene J, Bousquet J. The role of IgE in asthma. Clin Exp Allergy 1998; 28 (Suppl. 5):1049.
  • 172
    Townley RG, Ryo UY, Kolotkin BM, Kang B. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects. J Allergy Clin Immunol 1975; 56:42942.
  • 173
    Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 1984; 39:9128.
  • 174
    Gerblich AA, Schwartz HJ, Chester EH. Seasonal variation of airway function in allergic rhinitis. J Allergy Clin Immunol 1986; 77:67681.
  • 175
    Verdiani P, Di CS, Baronti A. Different prevalence and degree of nonspecific bronchial hyperreactivity between seasonal and perennial rhinitis. J Allergy Clin Immunol 1990; 86:57682.
  • 176
    Prieto JL, Gutierrez V, Berto JM, Camps B. Sensitivity and maximal response to methacholine in perennial and seasonal allergic rhinitis. Clin Exp Allergy 1996; 26:617.
  • 177
    Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:8793.
  • 178
    Lemanske RF Jr, Dick EC, Swenson CA, Vrtis RF, Busse WW. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 1989; 83:110.
  • 179
    Sterk PJ. Virus-induced airway hyperresponsiveness in man. Eur Respir J 1993; 6:894902.
  • 180
    Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992; 89:6118.
  • 181
    Aubier M, Levy J, Clerici C, Neukirch F, Cabrieres F, Herman D. Protective effect of theophylline on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1991; 143:34650.
  • 182
    Lowhagen O, Rak S. Modification of bronchial hyperreactivity after treatment with sodium cromoglycate during pollen season. J Allergy Clin Immunol 1985; 75:4607.
  • 183
    Sotomayor H, Badier M, Vervloet D, Orehek J. Seasonal increase of carbachol airway responsiveness in patients allergic to grass pollen. Reversal by corticosteroids. Am Rev Respir Dis 1984; 130:568.
  • 184
    Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107:46976.
  • 185
    Braunstahl GJ, Overbeek SE, Fokkens WJ et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001; 164:85865.
  • 186
    Sehmi R, Baatjes AJ, Denburg JA. Hemopoietic progenitor cells and hemopoietic factors: potential targets for treatment of allergic inflammatory diseases. Curr Drug Targets Inflamm Allergy 2003; 2:2718.
  • 187
    Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:5762.
  • 188
    Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002; 110:5864.
  • 189
    Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case–control study. J Allergy Clin Immunol 2004; 113:4159.
  • 190
    Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109:63642.
  • 191
    Corren J. The connection between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med 2007; 13:138.
  • 192
    Clement PA, Bluestone CD, Gordts F et al. Management of rhinosinusitis in children. Int J Pediatr Otorhinolaryngol 1999; 49 (Suppl. 1):S95100.
  • 193
    De Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005; 16:26775.
  • 194
    Ciprandi G, Ricca V, Passalacqua G et al. Seasonal rhinitis and azelastine: long- or short-term treatment? J Allergy Clin Immunol 1997; 99:3017.
  • 195
    Dykewicz MS, Kaiser HB, Nathan RA et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol 2003; 91:448.
  • 196
    Jen A, Baroody F, De TM, Haney L, Blair C, Naclerio R. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 105:7328.
  • 197
    Serra HA, Alves O, Rizzo LF, Devoto FM, Ascierto H. Loratadine–pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial. Br J Clin Pharmacol 1998; 45:14750.
  • 198
    Meltzer EO, Orgel HA, Biondi R et al. Ipratropium nasal spray in children with perennial rhinitis. Ann Allergy Asthma Immunol 1997; 78:48591.
  • 199
    Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:27480.
  • 200
    Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986; 41:2719.
  • 201
    Vourdas D, Syrigou E, Potamianou P et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53:66272.
  • 202
    LaRosa M., Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:42532.
  • 203
    Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol 1999; 9:30513.
  • 204
    Shusterman D. Toxicology of nasal irritants. Curr Allergy Asthma Rep 2003; 3:25865.
  • 205
    Drake-Lee A, Ruckley R, Parker A. Occupational rhinitis: a poorly diagnosed condition. J Laryngol Otol 2002; 116:5805.
  • 206
    Petrick MM, Slavin RG. Occupational rhinitis. Immunol Allergy Clin North Am 2003; 23:193203, vi.
  • 207
    Cullinan P, Cook A, Gordon S et al. Allergen exposure, atopy and smoking as determinants of allergy to rats in a cohort of laboratory employees. Eur Respir J 1999; 13:113943.
  • 208
    Gautrin D, Infante-Rivard C, Ghezzo H, Malo JL. Incidence and host determinants of probable occupational asthma in apprentices exposed to laboratory animals. Am J Respir Crit Care Med 2001; 163:899904.
  • 209
    Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals. Eur Respir J 2001; 17:9048.
  • 210
    Cartier A, Malo JL, Forest F et al. Occupational asthma in snow crab-processing workers. J Allergy Clin Immunol 1984; 74:2619.
  • 211
    Houba R, Heederik D, Doekes G. Wheat sensitization and work-related symptoms in the baking industry are preventable. An epidemiologic study. Am J Respir Crit Care Med 1998; 158:1499503.
  • 212
    Grammer LC, Ditto AM, Tripathi A, Harris KE. Prevalence and onset of rhinitis and conjunctivitis in subjects with occupational asthma caused by trimellitic anhydride (TMA). J Occup Environ Med 2002; 44:117981.
  • 213
    Wernfors M, Nielsen J, Schutz A, Skerfving S. Phthalic anhydride-induced occupational asthma. Int Arch Allergy Appl Immunol 1986; 79:7782.
  • 214
    Gwaltney JM. Clinical significance and pathogenesis of viral respiratory infections. Am J Med 2002; 112 (Suppl. 6A):13S8S.
  • 215
    Gwaltney JM Jr. Acute community acquired bacterial sinusitis: to treat or not to treat. Can Respir J 1999; 6 (Suppl. A):46A50A.
  • 216
    Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005; 26:84652.
  • 217
    Johnston SL, Pattemore PK, Sanderson G et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 1995; 310:12259.
  • 218
    Ramadan HH. Pediatric sinusitis: update. J Otolaryngol 2005; 34 (Suppl. 1):S147.
  • 219
    Fokkens W, Lund V, Bachert C et al. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 2005; 60:583601.
  • 220
    Leone C, Teodoro C, Pelucchi A et al. Bronchial responsiveness and airway inflammation in patients with nonallergic rhinitis with eosinophilia syndrome. J Allergy Clin Immunol 1997; 100:77580.
  • 221
    Garay R. Mechanisms of vasomotor rhinitis. Allergy 2004; 59 (Suppl. 76):49.
  • 222
    Yewell J, Haydon R, Archer S, Manaligod JM. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol 2002; 111:1747.
  • 223
    Hamano N, Terada N, Maesako K, Numata T, Konno A. Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 1998; 19:2639.
  • 224
    Philpott CM, El-Alami M, Murty GE. The effect of the steroid sex hormones on the nasal airway during the normal menstrual cycle. Clin Otolaryngol Allied Sci 2004; 29:13842.
  • 225
    Scadding GK. Non-allergic rhinitis: diagnosis and management. Curr Opin Allergy Clin Immunol 2001; 1:1520.
  • 226
    Bachert C. Persistent rhinitis – allergic or nonallergic? Allergy 2004; 59 (Suppl. 76):115.
  • 227
    Ferguson JL, McCaffrey TV, Kern EB, Martin WJ. Effect of Klebsiella ozaenae on ciliary activity in vitro: implications in the pathogenesis of atrophic rhinitis. Otolaryngol Head Neck Surg 1990; 102:20711.
  • 228
    Moore EJ, Kern EB. Atrophic rhinitis: a review of 242 cases. Am J Rhinol 2001; 15:35561.
  • 229
    Krzeski A, Kapiszewska-Dzedzej D, Gorski NP, Jakubczyk I. Cystic fibrosis in rhinologic practice. Am J Rhinol 2002; 16:15560.
  • 230
    Cottin V, Cordier JF. Churg–Strauss syndrome. Rev Pneumol Clin 2003; 59:1724.
  • 231
    Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Rheumatol 2001; 13:311.
  • 232
    Van Rijswijk JB, Boeke EL, Keizer JM, Mulder PG, Blom HM, Fokkens WJ. Intranasal capsaicin reduces nasal hyperreactivity in idiopathic rhinitis: a double-blind randomized application regimen study. Allergy 2003; 58:75461.
  • 233
    Van Rijswijk JB, Gerth van WR. Capsaicin treatment of idiopathic rhinitis: the new panacea? Curr Allergy Asthma Rep 2006; 6:1327.
  • 234
    Blom HM, Van Rijswijk JB, Garrelds IM, Mulder PG, Timmermans T, Gerth van WR. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. Clin Exp Allergy 1997; 27:796801.
  • 235
    Van Cauwenberge PB, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European academy of allergology and clinical immunology. Allergy 2000; 55:11634.


  1. Top of page
  2. Summary
  3. Introduction
  4. Executive summary and recommendations
  5. Definitions
  6. Classification and aetiology of rhinitis
  7. Diagnosis of rhinitis
  8. Treatment of rhinitis
  9. Rhinitis and pregnancy
  10. Co-morbid association
  11. Allergic rhinitis in children
  12. Future research
  13. Acknowledgements
  14. References
  15. Appendix

Appendix A

Table A1.   Recommendations on the use of single measures on HDM avoidance (letters in column 2 and 3 denote grade of recommendation)
Measures used individuallyIn favourAgainst
  • *

    May be useful if used as part of a range of measures to reduce HDM exposure.

  • HDM, house dust mite.

Encase mattress and pillows in plastic or special allergen proof fabricDA*
Hot wash bedding at 55°C and damp wipe mite proof covers every 1–2 weeksDNone
Remove carpets and replace with hard wood floorDNone
Use of acaricides on carpets and soft furnishingDNone
Minimise objects that accumulate dustDNone
Remove soft toys from the bed as they harbour high levels of Der p 1DNone
Remove upholstered furniture and replace with leather, plastic or vinyl furnitureDNone
Do not dry clothes on radiators and remove infrequently worn clothing from the bedroomDNone
Table A2.   Recommendations on the use of pollen avoidance measures
InterventionGrade of recommendation
Nasal filters (see [47]B
Minimizing early morning activity when the greatest pollen is emitted – after the dew dries after sunrise to late morningD
Avoiding going out after thunderstorms or on windy days when dust and pollen are blown aboutD
Wearing wraparound sunglassesD
Not mowing the grass, and staying inside when it is being mown. If mowing is unavoidable, wear a maskD
Planning holidays to avoid the pollen seasonD
Keeping windows closed both at home and particularly when in the car. In particular keeping windows closed at night to prevent pollens or moulds from drifting into the home. Instead, if needed, use air conditioning, which cleans, cools and dries the airD
If the patient is sensitized to a particular plant or tree – consider removalD
Shower and wash hair once homeD
Bathing eyes and douche nose frequentlyD
Staying indoors when the pollen count or humidity is reported to be highD
Bringing in washing before pollen levels increase in the eveningD
Table A3.   Recommendations on cat allergen avoidance measures
MeasureIn favour*Against
  • *

    Letters denote grade of recommendation.

Remove cat, followed by thorough cleaning of house, steam cleaning walls, shampooing carpetsDNone
Keeping cat out of bedroom and other commonly used roomsDNone
Washing cat weeklyDNone
Removing carpets and replacing with hardwood floors and cleaning regularlyDNone
Air filtration units in rooms where the patient spends the majority of their timeDNone
Increase ventilation with fans, air-conditioning or by opening windowsDNone
Table A4.   Grades of recommendation for various interventions
InterventionSeasonal allergic rhinitis (SAR)Perennial allergic rhinitis (PAR)
  1. CS, corticosteroid; SIT, specific immunotherapy.

Oral anti-H1AAAA
Intranasal anti-H1AAAA
Intranasal CSAAAA
Intranasal chromoneAAAA
Subcutaneous SITAAAA
Sublingual/nasal SITAAAA
Allergen avoidanceADDD